Hemophilia: Difference between revisions
(Created page with "==Factor 8== (weight in kg) x (50ml plasma/kg) x (desired F8 level - native F8 level) = total units* *half this dose should be readministered in 12 hours **DDAVP can also be ...") |
No edit summary |
||
| Line 1: | Line 1: | ||
==Factor 8== | ==Factor 8== | ||
(weight in kg) x (50ml plasma/kg) x (desired F8 level - native F8 level) = total units* | |||
<nowiki>*half this dose should be readministered in 12 hours</nowiki> | |||
<nowiki>**DDAVP can also be used (it raises factor 8 levels) as a supplement</nowiki> | |||
''' -- Recommended Factor VIII Therapy for Specific Problems in Hemophilia''' | |||
{| border="1" cellpadding="2" | |||
! align="left" | TYPE OF BLEEDING | |||
! align="left" | INITIAL DOSAGE | |||
! align="left" | DURATION | |||
! align="left" | COMMENT | |||
|- | |||
| colspan="4" align="left" | '''Skin''' | |||
|- | |||
| align="left" | Abrasion | |||
| align="left" | None | |||
| align="left" | None | |||
| align="left" | Treat with local pressure and topical thrombin | |||
|- | |||
| align="left" | Laceration | |||
| align="left" | Usually none; if necessary, treat as minor | |||
| align="left" | None | |||
| align="left" | Local pressure and anesthetic with epinephrine may benefit; watch 4 hours after suturing; reexamine in 24 hours | |||
|- | |||
| align="left" | Superficial | |||
| align="left" | | |||
| align="left" | | |||
| align="left" | | |||
|- | |||
| align="left" | Deep | |||
| align="left" | Minor bleeding (12.5 mg/kg) | |||
| align="left" | Single-dose coverage | |||
| align="left" | May need hospitalization for observation; repeat may be necessary for suture removal | |||
|- | |||
| align="left" | Nasal epistaxis | |||
| align="left" | | |||
| align="left" | | |||
| align="left" | | |||
|- | |||
| align="left" | Spontaneous | |||
| align="left" | Usually none; may need to be treated as mild bleeding | |||
| align="left" | None | |||
| align="left" | Uncommon; consider platelet inhibition; treat in usual manner | |||
|- | |||
| align="left" | Traumatic | |||
| align="left" | Moderate bleeding (25 mg/kg) | |||
| align="left" | Up to 5–7 days | |||
| align="left" | Trauma-related bleeding can be significant | |||
|- | |||
| colspan="4" align="left" | '''Oral''' | |||
|- | |||
| align="left" | Mucosa or tongue bites | |||
| align="left" | Usually none; treat as minor if persists | |||
| align="left" | Single dose | |||
| align="left" | Commonly seen | |||
|- | |||
| align="left" | Traumatic (laceration) or dental extraction | |||
| align="left" | Moderate (25 U/kg) to severe (50 U/kg) | |||
| align="left" | Single dose; may need more | |||
| align="left" | Saliva rich in fibrin lytic activity; oral ε-aminocaproic acid (Amicar) may be given at 100 mg every 6 hr for 7 days to block fibrinolysis; check contraindications; hospitalize patients with severe bleeding | |||
|- | |||
| align="left" | '''Soft tissue/muscle hematomas''' | |||
| align="left" | Moderate (25 U/kg) to severe (50 U/kg) | |||
| align="left" | 2–5 days | |||
| align="left" | May be complicated by local pressure on nerves or vessels (e.g., iliopsoas, forearm, calf) | |||
|- | |||
| colspan="4" align="left" | '''Hemarthrosis''' | |||
|- | |||
| align="left" | Early | |||
| align="left" | Mild (12.5 U/kg) | |||
| align="left" | Single dose | |||
| align="left" | Treat as earliest symptom (pain); knee, elbow, ankle more common | |||
|- | |||
| align="left" | Late or unresponsive cases of early hemarthrosis | |||
| align="left" | Mild to moderate (25 U/kg) | |||
| align="left" | 3–4 days | |||
| align="left" | Arthrocentesis rarely necessary and only with 50% level coverage; immobilization is critical point of therapy | |||
|- | |||
| align="left" | '''Hematuria''' | |||
| align="left" | Mild (12.5 U/kg) | |||
| align="left" | 2–3 days | |||
| align="left" | Urokinase, the fibrinolytic enzyme, is in urine; with persistent hematuria an organic cause should be ruled out | |||
|- | |||
| align="left" | Major bleeding | |||
| align="left" | Major bleeding (50 U/kg) | |||
| align="left" | 7–10 days or 3–5 days after bleeding ceases | |||
| align="left" | In head trauma, therapy should be given prophylactically; early CT scan of head recommended for all | |||
|- | |||
| align="left" | Gastrointestinal severe bleeding | |||
| align="left" | | |||
| align="left" | | |||
| align="left" | | |||
|- | |||
| align="left" | Neck/sublingual | |||
| align="left" | | |||
| align="left" | | |||
| align="left" | | |||
|- | |||
| align="left" | Retroperitoneal | |||
| align="left" | | |||
| align="left" | | |||
| align="left" | | |||
|- | |||
| align="left" | Intra-abdominal | |||
| align="left" | | |||
| align="left" | | |||
| align="left" | | |||
|- | |||
| align="left" | Major trauma | |||
| align="left" | | |||
| align="left" | | |||
| align="left" | | |||
|- | |||
| align="left" | Head injury (see text) | |||
| align="left" | | |||
| align="left" | | |||
| align="left" | | |||
|- | |||
| align="left" | Central nervous system bleeding (see text) | |||
| align="left" | | |||
| align="left" | | |||
| align="left" | | |||
|- | |||
| align="left" | Surgical procedure | |||
| align="left" | | |||
| align="left" | | |||
| align="left" | | |||
|} | |||
{| width="100%" | |||
| align="left" | | |||
CT, computed tomography | |||
|} | |||
''' ''''''-- Dosage of Factor VIII (Antihemophilic Factor)''' | |||
{| border="1" cellpadding="2" | |||
! align="left" | BLEEDING RISK | |||
! align="left" | DESIRED FACTOR VIII LEVEL (%) | |||
! align="left" | INITIAL DOSE (U/KG) | |||
|- | |||
| align="left" | Mild | |||
| align="left" | 5–10 | |||
| align="left" | 12.5 | |||
|- | |||
| align="left" | Moderate | |||
| align="left" | 20–30 | |||
| align="left" | 25 | |||
|- | |||
| align="left" | Severe | |||
| align="left" | 50 or greater | |||
| align="left" | 50 | |||
|} | |||
{| width="100%" | |||
| align="left" | | |||
Standard Calculation | |||
{| | |||
| width="2" | | |||
| width="4%" valign="top" | '''1.''' | |||
| Patient's plasma volume (50 mL/kg × weight in kg) × (Desired level of factor VIII [percent]) − (Present level of factor VIII [percent]) = Number of units for initial dose.<br /> | |||
|- | |||
| width="2" | | |||
| width="4%" valign="top" | '''2.''' | |||
| In emergency therapy, the present level of factor VIII is assumed to be zero.<br /> | |||
|- | |||
| width="2" | | |||
| width="4%" valign="top" | '''3.''' | |||
| One unit is the activity of the coagulation factor present in 1 mL of normal human plasma.<br /> | |||
|- | |||
| width="2" | | |||
| width="4%" valign="top" | '''4.''' | |||
| Because the half-life of factor VIII is 8–12 hr, the desired level is maintained by giving half the initial dose every 8–12 hr.<br /> | |||
|- | |||
| width="2" | | |||
| width="4%" valign="top" | '''5.''' | |||
| Cryoprecipitate is assumed to have 80–100 U of factor VIII:C per bag; factor VIII:C concentrates list the units per bottle on the label. | |||
|} | |||
|} | |||
==Factor 9== | |||
(weight in kg) x (100ml plasma/kg) x (desired F9 level - native F9 level) = total units* | |||
<nowiki>*half this dose should be readministered in 24 hours</nowiki> | |||
<nowiki>**DDAVP is not helpful in F9 deficiency</nowiki> | |||
==Source== | |||
DONALDSON 10/08 (From "Kaji Questions"), Rosen's | |||
<div id="wikiedit" style="display: none"><div id="editor-panel" class="box"> | |||
=Hemophilia[/rename.php?renamepage=Hemophilia ]= | |||
{| id="edit-panel" style="table-layout: fixed; width: 100%" | |||
|- | |||
| | |||
<div id="editframe"></div><div id="edit-toolbar-outer" style="background: #f7f7f7; border: 1px solid #ddd; border-top: 1px solid #f7f7f7"><div id="revcomment_section" style="display: none"><div id="revcomment_top">Describe your changes:[# (hide this)]</div><div class="entry"></div></div><div id="edit-toolbar" class="secondarypagetoolbar"><span id="show_tags" style="float: right; margin: 5px">Edit tags</span><span id="show_revcomment" style="float: right; margin: 5px">Describe your changes</span><span id="autosave_msg" class="aux"></span>[#pbedit <span id="saveButton" class="iconbutton savepage">'''Save'''</span>][# <span id="saveAndContinue" class="iconbutton savecontinue" style="position: relative">Save and Continue</span>]<span style="line-height: 30px">or [/w/page/11229420/Hemophilia?unlock=true Cancel]</span><span id="save_msg" class="aux loading"></span></div><div style="clear: both; line-height: 1px"><font size="1px"> </font></div><div id="tag-settings" class="page-settings-panel" style="margin-top: 0.75em; display: none"> | |||
{| width="100%" | |||
| style="width: 4em" | | |||
Tags | |||
| | |||
e.g. report, new release, planning | |||
|} | |||
<div style="clear: both; line-height: 1px"><font size="1px"> </font></div><div id="tagcloud"></div></div></div> | |||
| | |||
<div id="editor-column" class="thingbar" style="margin-left: 12px"><div id="edit-tools"> | |||
====Page Tools==== | |||
[/rename.php?renamepage=Hemophilia Rename this page] [# Delete this page]<div class="editor-module"><div class="header"> | |||
===Insert links=== | |||
Insert links to other pages or uploaded files. | |||
</div><div class="editor-module-tabs">[# Pages] [# Images and files]</div><div class="content"><div id="thingbar-pages" style="display: none"><div style="border-bottom: 1px dotted #bbb; padding-bottom: 0.5em; margin-bottom: 0.5em"><font size="10px">[javascript:void(0); Insert a link to a new page]</font></div> | |||
# <div><center><span id="thingbarLoadIcon"></span> Loading...</center></div> | |||
</div><div id="thingbar-images" style="display: none"><div id="thingbar-upload" style="border-bottom: 1px dotted #bbb; padding-bottom: 0.5em; margin-bottom: 0.5em"><font size="10px"></font></div> | |||
# No images or files uploaded yet. | |||
<div style="border-top: 1px dotted #bbb; padding-top: 0.5em; margin-top: 0.5em"><font size="10px">[javascript:void(0); Insert image from URL]</font></div></div></div></div></div> | |||
'''Tip:''' To turn text into a link, highlight the text, then click on a page or file from the list above. | |||
</div> | |||
|} | |||
</div></div> | |||
== <br/> == | |||
== <br/> == | |||
== <br/> == | |||
== Factor 8 == | |||
(weight in kg) x (50ml plasma/kg) x (desired F8 level - native F8 level) = total units* | (weight in kg) x (50ml plasma/kg) x (desired F8 level - native F8 level) = total units* | ||
| Line 8: | Line 256: | ||
**DDAVP can also be used (it raises factor 8 levels) as a supplement | **DDAVP can also be used (it raises factor 8 levels) as a supplement | ||
-- Recommended Factor VIII Therapy for Specific Problems in Hemophilia | -- Recommended Factor VIII Therapy for Specific Problems in Hemophilia | ||
TYPE OF BLEEDINGINITIAL DOSAGEDURATIONCOMMENT | TYPE OF BLEEDINGINITIAL DOSAGEDURATIONCOMMENT Skin Abrasion None None Treat with local pressure and topical thrombin Laceration Usually none; if necessary, treat as minor None Local pressure and anesthetic with epinephrine may benefit; watch 4 hours after suturing; reexamine in 24 hours Superficial Deep Minor bleeding (12.5 mg/kg) Single-dose coverage May need hospitalization for observation; repeat may be necessary for suture removal Nasal epistaxis Spontaneous Usually none; may need to be treated as mild bleeding None Uncommon; consider platelet inhibition; treat in usual manner Traumatic Moderate bleeding (25 mg/kg) Up to 5–7 days Trauma-related bleeding can be significant Oral Mucosa or tongue bites Usually none; treat as minor if persists Single dose Commonly seen Traumatic (laceration) or dental extraction Moderate (25 U/kg) to severe (50 U/kg) Single dose; may need more Saliva rich in fibrin lytic activity; oral ε-aminocaproic acid (Amicar) may be given at 100 mg every 6 hr for 7 days to block fibrinolysis; check contraindications; hospitalize patients with severe bleeding Soft tissue/muscle hematomas Moderate (25 U/kg) to severe (50 U/kg) 2–5 days May be complicated by local pressure on nerves or vessels (e.g., iliopsoas, forearm, calf) Hemarthrosis Early Mild (12.5 U/kg) Single dose Treat as earliest symptom (pain); knee, elbow, ankle more common Late or unresponsive cases of early hemarthrosis Mild to moderate (25 U/kg) 3–4 days Arthrocentesis rarely necessary and only with 50% level coverage; immobilization is critical point of therapy Hematuria Mild (12.5 U/kg) 2–3 days Urokinase, the fibrinolytic enzyme, is in urine; with persistent hematuria an organic cause should be ruled out Major bleeding Major bleeding (50 U/kg) 7–10 days or 3–5 days after bleeding ceases In head trauma, therapy should be given prophylactically; early CT scan of head recommended for all Gastrointestinal severe bleeding Neck/sublingual Retroperitoneal Intra-abdominal Major trauma Head injury (see text) Central nervous system bleeding (see text) Surgical procedure CT, computed tomography | ||
Skin | |||
Abrasion None None Treat with local pressure and topical thrombin | |||
Laceration Usually none; if | |||
Superficial | |||
Deep Minor | |||
Nasal | |||
Spontaneous Usually none; may need to be treated as mild bleeding None Uncommon; consider platelet | |||
Traumatic Moderate bleeding (25 mg/kg) Up to 5–7 days Trauma-related bleeding | |||
Oral | |||
Mucosa or tongue bites Usually none; | |||
Traumatic | |||
Soft | |||
Hemarthrosis | |||
Early Mild (12.5 U/kg) Single dose Treat as earliest symptom | |||
Late or unresponsive cases of early hemarthrosis Mild | |||
Hematuria Mild (12.5 U/kg) 2–3 days Urokinase, the fibrinolytic | |||
Major bleeding Major bleeding (50 U/kg) 7–10 days or | |||
Gastrointestinal | |||
Neck/sublingual | |||
Retroperitoneal | |||
Intra-abdominal | |||
Major trauma | |||
Head injury (see text) | |||
Central nervous system bleeding (see text) | |||
Surgical procedure | |||
CT, computed tomography | |||
-- Dosage of Factor VIII (Antihemophilic Factor) | -- Dosage of Factor VIII (Antihemophilic Factor) | ||
BLEEDING RISKDESIRED FACTOR VIII | BLEEDING RISKDESIRED FACTOR VIII LEVEL (%)INITIAL DOSE (U/KG) Mild 5–10 12.5 Moderate 20–30 25 Severe 50 or greater 50 Standard Calculation | ||
Mild 5–10 12.5 | |||
Moderate 20–30 25 | |||
Severe 50 or greater 50 | |||
Standard Calculation | |||
1. Patient's plasma volume (50 mL/kg × weight in kg) × (Desired level of factor VIII [percent]) − (Present level of factor VIII [percent]) = Number of units for initial dose. | 1. Patient's plasma volume (50 mL/kg × weight in kg) × (Desired level of factor VIII [percent]) − (Present level of factor VIII [percent]) = Number of units for initial dose. | ||
| Line 56: | Line 275: | ||
4. Because the half-life of factor VIII is 8–12 hr, the desired level is maintained by giving half the initial dose every 8–12 hr. | 4. Because the half-life of factor VIII is 8–12 hr, the desired level is maintained by giving half the initial dose every 8–12 hr. | ||
5. Cryoprecipitate is assumed to have 80–100 U of factor VIII:C per bag; factor VIII:C concentrates list the units per bottle on the label. | 5. Cryoprecipitate is assumed to have 80–100 U of factor VIII:C per bag; factor VIII:C concentrates list the units per bottle on the label. | ||
== Factor 9 == | |||
(weight in kg) x (100ml plasma/kg) x (desired F9 level - native F9 level) = total units* | (weight in kg) x (100ml plasma/kg) x (desired F9 level - native F9 level) = total units* | ||
| Line 70: | Line 288: | ||
**DDAVP is not helpful in F9 deficiency | **DDAVP is not helpful in F9 deficiency | ||
== Source == | |||
DONALDSON 10/08 (From "Kaji Questions"), Rosen's | DONALDSON 10/08 (From "Kaji Questions"), Rosen's | ||
<br/>[[Category:Heme/Onc]] | |||
[[Category:Heme/Onc]] | |||
Revision as of 05:17, 12 March 2011
Factor 8
(weight in kg) x (50ml plasma/kg) x (desired F8 level - native F8 level) = total units*
*half this dose should be readministered in 12 hours
**DDAVP can also be used (it raises factor 8 levels) as a supplement
-- Recommended Factor VIII Therapy for Specific Problems in Hemophilia
| TYPE OF BLEEDING | INITIAL DOSAGE | DURATION | COMMENT |
|---|---|---|---|
| Skin | |||
| Abrasion | None | None | Treat with local pressure and topical thrombin |
| Laceration | Usually none; if necessary, treat as minor | None | Local pressure and anesthetic with epinephrine may benefit; watch 4 hours after suturing; reexamine in 24 hours |
| Superficial | |||
| Deep | Minor bleeding (12.5 mg/kg) | Single-dose coverage | May need hospitalization for observation; repeat may be necessary for suture removal |
| Nasal epistaxis | |||
| Spontaneous | Usually none; may need to be treated as mild bleeding | None | Uncommon; consider platelet inhibition; treat in usual manner |
| Traumatic | Moderate bleeding (25 mg/kg) | Up to 5–7 days | Trauma-related bleeding can be significant |
| Oral | |||
| Mucosa or tongue bites | Usually none; treat as minor if persists | Single dose | Commonly seen |
| Traumatic (laceration) or dental extraction | Moderate (25 U/kg) to severe (50 U/kg) | Single dose; may need more | Saliva rich in fibrin lytic activity; oral ε-aminocaproic acid (Amicar) may be given at 100 mg every 6 hr for 7 days to block fibrinolysis; check contraindications; hospitalize patients with severe bleeding |
| Soft tissue/muscle hematomas | Moderate (25 U/kg) to severe (50 U/kg) | 2–5 days | May be complicated by local pressure on nerves or vessels (e.g., iliopsoas, forearm, calf) |
| Hemarthrosis | |||
| Early | Mild (12.5 U/kg) | Single dose | Treat as earliest symptom (pain); knee, elbow, ankle more common |
| Late or unresponsive cases of early hemarthrosis | Mild to moderate (25 U/kg) | 3–4 days | Arthrocentesis rarely necessary and only with 50% level coverage; immobilization is critical point of therapy |
| Hematuria | Mild (12.5 U/kg) | 2–3 days | Urokinase, the fibrinolytic enzyme, is in urine; with persistent hematuria an organic cause should be ruled out |
| Major bleeding | Major bleeding (50 U/kg) | 7–10 days or 3–5 days after bleeding ceases | In head trauma, therapy should be given prophylactically; early CT scan of head recommended for all |
| Gastrointestinal severe bleeding | |||
| Neck/sublingual | |||
| Retroperitoneal | |||
| Intra-abdominal | |||
| Major trauma | |||
| Head injury (see text) | |||
| Central nervous system bleeding (see text) | |||
| Surgical procedure | |||
|
CT, computed tomography |
' '-- Dosage of Factor VIII (Antihemophilic Factor)
| BLEEDING RISK | DESIRED FACTOR VIII LEVEL (%) | INITIAL DOSE (U/KG) |
|---|---|---|
| Mild | 5–10 | 12.5 |
| Moderate | 20–30 | 25 |
| Severe | 50 or greater | 50 |
|
Standard Calculation
|
Factor 9
(weight in kg) x (100ml plasma/kg) x (desired F9 level - native F9 level) = total units*
*half this dose should be readministered in 24 hours
**DDAVP is not helpful in F9 deficiency
Source
DONALDSON 10/08 (From "Kaji Questions"), Rosen's
Factor 8
(weight in kg) x (50ml plasma/kg) x (desired F8 level - native F8 level) = total units*
- half this dose should be readministered in 12 hours
- DDAVP can also be used (it raises factor 8 levels) as a supplement
-- Recommended Factor VIII Therapy for Specific Problems in Hemophilia
TYPE OF BLEEDINGINITIAL DOSAGEDURATIONCOMMENT Skin Abrasion None None Treat with local pressure and topical thrombin Laceration Usually none; if necessary, treat as minor None Local pressure and anesthetic with epinephrine may benefit; watch 4 hours after suturing; reexamine in 24 hours Superficial Deep Minor bleeding (12.5 mg/kg) Single-dose coverage May need hospitalization for observation; repeat may be necessary for suture removal Nasal epistaxis Spontaneous Usually none; may need to be treated as mild bleeding None Uncommon; consider platelet inhibition; treat in usual manner Traumatic Moderate bleeding (25 mg/kg) Up to 5–7 days Trauma-related bleeding can be significant Oral Mucosa or tongue bites Usually none; treat as minor if persists Single dose Commonly seen Traumatic (laceration) or dental extraction Moderate (25 U/kg) to severe (50 U/kg) Single dose; may need more Saliva rich in fibrin lytic activity; oral ε-aminocaproic acid (Amicar) may be given at 100 mg every 6 hr for 7 days to block fibrinolysis; check contraindications; hospitalize patients with severe bleeding Soft tissue/muscle hematomas Moderate (25 U/kg) to severe (50 U/kg) 2–5 days May be complicated by local pressure on nerves or vessels (e.g., iliopsoas, forearm, calf) Hemarthrosis Early Mild (12.5 U/kg) Single dose Treat as earliest symptom (pain); knee, elbow, ankle more common Late or unresponsive cases of early hemarthrosis Mild to moderate (25 U/kg) 3–4 days Arthrocentesis rarely necessary and only with 50% level coverage; immobilization is critical point of therapy Hematuria Mild (12.5 U/kg) 2–3 days Urokinase, the fibrinolytic enzyme, is in urine; with persistent hematuria an organic cause should be ruled out Major bleeding Major bleeding (50 U/kg) 7–10 days or 3–5 days after bleeding ceases In head trauma, therapy should be given prophylactically; early CT scan of head recommended for all Gastrointestinal severe bleeding Neck/sublingual Retroperitoneal Intra-abdominal Major trauma Head injury (see text) Central nervous system bleeding (see text) Surgical procedure CT, computed tomography
-- Dosage of Factor VIII (Antihemophilic Factor)
BLEEDING RISKDESIRED FACTOR VIII LEVEL (%)INITIAL DOSE (U/KG) Mild 5–10 12.5 Moderate 20–30 25 Severe 50 or greater 50 Standard Calculation
1. Patient's plasma volume (50 mL/kg × weight in kg) × (Desired level of factor VIII [percent]) − (Present level of factor VIII [percent]) = Number of units for initial dose. 2. In emergency therapy, the present level of factor VIII is assumed to be zero. 3. One unit is the activity of the coagulation factor present in 1 mL of normal human plasma. 4. Because the half-life of factor VIII is 8–12 hr, the desired level is maintained by giving half the initial dose every 8–12 hr. 5. Cryoprecipitate is assumed to have 80–100 U of factor VIII:C per bag; factor VIII:C concentrates list the units per bottle on the label.
Factor 9
(weight in kg) x (100ml plasma/kg) x (desired F9 level - native F9 level) = total units*
- half this dose should be readministered in 24 hours
- DDAVP is not helpful in F9 deficiency
Source
DONALDSON 10/08 (From "Kaji Questions"), Rosen's
